First patient successfully treated with ChemoSeed

Summary by AI BETAClose X

CRISM Therapeutics announced that the first patient has been treated with its irinotecan ChemoSeed implant as part of its registration-grade Phase II glioblastoma trial; the implantation was completed without procedural complications, the patient remained clinically stable with no post-operative seizures, and scheduled post-operative assessments and ongoing recruitment will continue, initiating clinical data generation toward safety and efficacy readouts that could materially derisk the programme; separate preclinical data show a 58% tumour‑volume reduction for docetaxel‑ChemoSeed.

Disclaimer*

UK 100

Latest directors dealings